drugset / Trial / NCT05631990

A Study to Evaluate the Efficacy and Safety of AD-209

NCT05631990

Phase 2 Completed 221 enrolled Addpharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-209

Timeline

Start
2023-04-05
Primary completion
2023-11-27
Completion
2023-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-209-1A Unknown Oral
Subject AD-209-1B Unknown Oral
Subject AD-209-1C Unknown Oral
Subject AD209 Unknown Oral